EP4277613A4 - Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation - Google Patents

Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation Download PDF

Info

Publication number
EP4277613A4
EP4277613A4 EP22740195.7A EP22740195A EP4277613A4 EP 4277613 A4 EP4277613 A4 EP 4277613A4 EP 22740195 A EP22740195 A EP 22740195A EP 4277613 A4 EP4277613 A4 EP 4277613A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
pharmaceutical compositions
breast cancer
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22740195.7A
Other languages
German (de)
English (en)
Other versions
EP4277613A1 (fr
Inventor
Mitchell Steiner
Ramesh Narayanan
Sunjoo Ahn
James Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of EP4277613A1 publication Critical patent/EP4277613A1/fr
Publication of EP4277613A4 publication Critical patent/EP4277613A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP22740195.7A 2021-01-15 2022-01-14 Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation Pending EP4277613A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (fr) 2021-01-15 2022-01-14 Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP4277613A1 EP4277613A1 (fr) 2023-11-22
EP4277613A4 true EP4277613A4 (fr) 2024-11-20

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22740195.7A Pending EP4277613A4 (fr) 2021-01-15 2022-01-14 Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation

Country Status (10)

Country Link
EP (1) EP4277613A4 (fr)
JP (1) JP2024503718A (fr)
KR (1) KR20230163362A (fr)
CN (1) CN116981451A (fr)
AU (1) AU2022208712A1 (fr)
BR (1) BR112023014247A2 (fr)
CA (1) CA3205212A1 (fr)
IL (1) IL304467A (fr)
MX (1) MX2023008375A (fr)
WO (1) WO2022155543A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (fr) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 Antagoniste du récepteur des androgènes de propionamide, son procédé de préparation et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209407A1 (en) * 2012-07-13 2017-07-27 Gtx, Inc. Method of treating her2-positive breast cancers with selective androgen receptor modulators (sarms)
WO2020028593A1 (fr) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. Méthode de traitement de cancers du sein exprimant un mutant er avec des modulateurs sélectifs du récepteur des androgènes (sarm)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2020206035A1 (fr) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Traitement de troubles néoplasiques résistant aux inhibiteurs de cdk4/6

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209407A1 (en) * 2012-07-13 2017-07-27 Gtx, Inc. Method of treating her2-positive breast cancers with selective androgen receptor modulators (sarms)
WO2020028593A1 (fr) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. Méthode de traitement de cancers du sein exprimant un mutant er avec des modulateurs sélectifs du récepteur des androgènes (sarm)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAFNER MARC ET AL: "Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 8, 6 June 2019 (2019-06-06), pages 1067, XP085774751, ISSN: 2451-9456, [retrieved on 20190606], DOI: 10.1016/J.CHEMBIOL.2019.05.005 *
HICKEY THERESA E. ET AL: "The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer", NATURE MEDICINE, vol. 27, no. 2, 18 January 2021 (2021-01-18), New York, pages 310 - 320, XP093321455, ISSN: 1078-8956, DOI: 10.1038/s41591-020-01168-7 *
LYONS TOMAS G ET AL: "Androgen Receptor-Targeted Therapy for Breast Cancer", CURRENT BREAST CANCER REPORTS, SPRINGER US, BOSTON, vol. 9, no. 4, 24 October 2017 (2017-10-24), pages 242 - 250, XP036367246, ISSN: 1943-4588, [retrieved on 20171024], DOI: 10.1007/S12609-017-0261-8 *
See also references of WO2022155543A1 *
WENFEI JI ET AL: "Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 15, no. 3, 1 January 2019 (2019-01-01), pages 522 - 532, XP055558235, ISSN: 1449-2288, DOI: 10.7150/ijbs.30572 *

Also Published As

Publication number Publication date
BR112023014247A2 (pt) 2023-10-03
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31
MX2023008375A (es) 2023-10-05
EP4277613A1 (fr) 2023-11-22
WO2022155543A1 (fr) 2022-07-21
CA3205212A1 (fr) 2022-07-21
IL304467A (en) 2023-09-01
AU2022208712A9 (en) 2024-09-19
JP2024503718A (ja) 2024-01-26
KR20230163362A (ko) 2023-11-30

Similar Documents

Publication Publication Date Title
EP4034138A4 (fr) Compositions et procédés pour le traitement de cancers liquides
EP4473970A4 (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4196113A4 (fr) Compositions pharmaceutiques et méthodes de traitement de la maladie de parkinson
EP3777888A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP4373939A4 (fr) Compositions d'édition de génome et méthodes de traitement de maladie granulomateuse chronique
EP4139454A4 (fr) Compositions de traitement du cancer avec des mutations demutations et leurs utilisations
EP4277613A4 (fr) Compositions pharmaceutiques pour le traitement de cancers du sein et leurs méthodes d'utilisation
EP3990119A4 (fr) Méthodes et compositions comprenant des thérapies d'activation de brd9, permettant le traitement de cancers et de troubles apparentés
EP4151227A4 (fr) Composition pharmaceutique pour le traitement du cancer
EP4003351A4 (fr) Méthodes et compositions pour le traitement du cancer
EP4410308A4 (fr) Agent thérapeutique induisant la cytotoxicité destiné à être utilisé dans le traitement du cancer
EP4499625A4 (fr) Compositions et méthodes de traitement du cancer
EP4408464A4 (fr) Méthodes de traitement du cancer et compositions pharmaceutiques associées
EP4412613A4 (fr) Méthodes de traitement de cancers et de tumeurs
EP4188346A4 (fr) Compositions de nobiletine et méthodes pour le traitement et la prévention de la covid-19 et de pathologies associées
EP4114411A4 (fr) Compositions et méthodes pour le traitement du cancer du pancréas
EP4467140A4 (fr) Combinaison pharmaceutique pour le traitement de tumeurs et son utilisation
EP3999065C0 (fr) Compositions thérapeutiques et procédés comprenant idelalisib and defactinibde traitement de cancers du sein
EP4244390A4 (fr) Compositions et méthodes d'identification, d?évaluation et de traitement d'un patient atteint d'un cancer
EP4262763A4 (fr) Mimétiques de smac pour le traitement du cancer, leur procédé de préparation et leur composition pharmaceutique
EP4228696A4 (fr) Compositions et procédés pour traitement de troubles sanguins
EP4157246C0 (fr) Association thérapeutique pour le traitement du cancer du sein
EP4237094A4 (fr) Compositions pharmaceutiques et leurs méthodes d'utilisation pour le traitement d'un cancer
EP3999112A4 (fr) Compositions de vaccin contre le cancer et ses méthodes d'utilisation pour prévenir et/ou traiter le cancer
EP4469559A4 (fr) Compositions et méthodes de traitement de cancers positifs à la mésothéline

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031167000

Ipc: A61K0031277000

A4 Supplementary search report drawn up and despatched

Effective date: 20241021

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20241015BHEP

Ipc: A61K 31/519 20060101ALI20241015BHEP

Ipc: A61K 31/506 20060101ALI20241015BHEP

Ipc: A61K 45/06 20060101ALI20241015BHEP

Ipc: A61K 31/167 20060101ALI20241015BHEP

Ipc: A61K 31/277 20060101AFI20241015BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251030